-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the New England Journal of Medicine (NEJM) published two important studies at the same time, analyzing patients who had symptoms of thrombosis and thrombocytopenia after being vaccinated with the adenovirus new crown vaccine ChAdOx1 nCoV-19.
In the first study, the Norwegian research team reported that 5 cases of rare venous thrombosis and thrombocytopenia were found in more than 130,000 vaccinators.
High levels of antibodies against PF4-polyanion complex were detected in the blood of all patients.
In the second study, the German research team analyzed the clinical and blood test data of 11 patients who experienced thrombosis or thrombocytopenia after being vaccinated with the ChAdOx1 nCov-19 new crown vaccine in Germany and Austria.
The researchers pointed out in the discussion session that historical studies have shown that other factors besides heparin may also trigger symptoms that are very similar to heparin-induced thrombocytopenia.
The clinical symptoms of patients with thrombosis and thrombocytopenia after the ChAdOx1 nCov-19 new crown vaccine are very similar to these patients.
Although the main purpose of these two studies is not to explore treatments for this symptom, the researchers provide potential strategies for diagnosing and treating these symptoms.
Reference materials:
Reference materials:[1] Schultz et al.
[1] Schultz et al.
[2] Greinacher et al.
▽ attention [drug Mingkang Germany ] micro-channel public number
[Medical attention Mingkang Germany ] ] micro-channel public number
